Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Votrient
Pazopanib is a small molecule tyrosine kinase inhibitor (TKI) primarily used in the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS). It works by blocking several receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-Kit, which are involved in tumor growth and angiogenesis.
For the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS).
Severe liver injury, including fatal hepatic failure, has been reported. Monitor liver function tests before starting and during treatment. Hepatotoxicity may occur at any time during therapy, including after prolonged treatment. Pazopanib can cause severe and fatal hemorrhage. Discontinue pazopanib in patients with severe hemorrhage.
Outcome:
Decreased pazopanib levels, reduced efficacy
Mechanism:
Increased metabolism of pazopanib
Outcome:
Increased risk of bleeding
Mechanism:
Pazopanib may inhibit platelet function
Outcome:
No clinically significant interaction expected
Mechanism:
Different metabolic pathways
Most likely new formulation: Pazopanib nanoformulation for improved delivery and reduced toxicity (Year: 2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of pazopanib expanding its indications to include other solid tumors in the next 5 years.
Tyrosine Kinase Inhibitor, Antineoplastic Agent
Indolinone